ArriVent BioPharma
Develops licensed oncology assets led by firmonertinib and antibody-drug conjugates.
$30.17
After-hours close−0.05 (−0.17%)
At close$30.22(−2.52%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.07 | — | — |
| Aug 2026 | −$0.99 | −$1.05 | −6.3% |
| May 2026 | −$0.88 | −$0.96 | −9.1% |
| Mar 2026 | −$0.87 | −$0.78 | +10.3% |
| Nov 2025 | −$0.78 | −$0.83 | −6.4% |
The latest year is open to everyone — the 14 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Jan 2024 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | −$1.07 | — | — | $800.0K | — | — |
| Aug 12, 2026 | −$0.99 | −$1.05 | −6.3% | — | — | — |
| May 11, 2026 | −$0.88 | −$0.96 | −9.1% | — | — | — |
| Mar 5, 2026 | −$0.87 | −$0.78 | +10.3% | — | — | — |
| Nov 10, 2025 | −$0.78 | −$0.83 | −6.4% | — | — | — |
The latest year is open to everyone — the 14 quarters behind it read with an account. Sign in | ||||||
| Aug 11, 2025 | ||||||
| May 12, 2025 | ||||||
| Mar 3, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 8, 2024 | ||||||
| Jan 26, 2024 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Dec 30, 2022 | ||||||
| Sep 29, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||